Home > Boards > US OTC > Medical - Equipment >

RedHawk Holdings Corp. (SNDD)

SNDD RSS Feed
Add SNDD Price Alert      Hide Sticky   Hide Intro
Moderator: Golden_Cross, sony12, ThoughtPower, MNKD_RISE, times2times2, Cowpie88
Search This Board: 
Last Post: 9/15/2019 1:58:35 AM - Followers: 318 - Board type: Free - Posts Today: 4

RedHawk Holdings Corp.
 

About RedHawk Holdings Corp.

RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the Disintegrator™ Insulin Needle Destruction Unit, the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.


       The Company believes the new name will better reflect the future direction of the business. The Company also said its
                      health care business unit will operate as a fully-owned subsidiary of RedHawk under the name Independence Health Corp., LLC.

The Company is waiting for regulatory approval to begin trading under its new trading symbol (HAWC) and new CUSIP number (75746Q103).


http://www.redhawkholdingscorp.com

http://www.redhawkenergycorp.com

https://ecogen-europe.co.uk
http://redhawkmedical.co.uk



 

         A/S: 2 Billion - per state of Nevada active status

O/S: 454,180,482 Million - as of Sep 5, 2018


Float: 181,225,775 million - as of Jun 07, 2017

3,000 Shareholders of Record a/o Sep 15, 2017

Insiders Own 60%+ = Over 200 Million Shares
                                                                       


*******Recent news*******


RedHawk Initiates Plan to Eliminate Debt
 

LAFAYETTE, La., Dec. 13, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (IDNG) (“RedHawk” or the “Company”) announced today that it has received a favorable order from the Circuit Court of the Twelfth Judicial Circuit Court in the State of Florida (Case No. 2017 CA 5554) granting the Company approval of a settlement transaction (the “Transaction”) for RedHawk to issue up to $117,000 of its common stock (“Issued Shares”) in full satisfaction of up to $153,000 of 3rd party trade obligations and broker fees. The Issued Shares are exempt from registration pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended, and will be issued at a 35% discount to market, as defined.

Simultaneous with announcing the Transaction, RedHawk said it has entered into a common stock purchase and sale agreement (the “Purchase and Sale Agreement”) with Beechwood Properties, LLC (“Beechwood”) who beneficially owns approximately 60% of the Company’s outstanding common stock. Mr. G. Darcy Klug, the Company’s Chairman of the Board and Chief Financial Officer owns and controls Beechwood.

Under the terms of the Purchase and Sale Agreement, RedHawk has agreed to purchase from Beechwood a like number shares (the “Beechwood Shares”) to be issued under the Transaction. The purchase price for the Beechwood Shares is also $117,000 and will be paid with the issuance of a promissory note (the “Note”) to Beechwood. The Note will accrue interest at 5% per annum and will mature three years from date of issuance. After two years from its issuance, the Note and any accrued interest, will become convertible into the Company’s Series A Preferred Stock.

The Company said the Transaction and the Sale and Purchase Agreement were entered into with the objective of continuing to restructure the Company’s balance sheet by eliminating approximately $153,000 of 3rd party debt from the balance sheet, preventing shareholder dilution with the Transaction, and preserving cash to be used for future operations and strategic transactions. Additionally, RedHawk said, upon completion of the Transaction, the Beechwood Shares will be returned into the Company’s treasury with no increase in the number of outstanding shares.


RedHawk Completes EcoGen Share Transfer Agreement

LAFAYETTE, La., Dec. 11, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (IDNG) (“RedHawk” or the “Company”) announced today that along with its wholly-owned subsidiary, RedHawk Pharma UK Limited (“RedHawk Pharma”), it has completed the previously announced share transfer agreement (“Share Transfer Agreement”) with Scarlett Pharma Limited (“Scarlett”), its affiliate, Warwick Healthcare Limited (“Warwick”) and the shareholders of Scarlett and Warwick.

Under the terms of the Share Transfer Agreement, amongst other consideration, RedHawk Pharma assumed approximately $370,000 of obligations due to EcoGen by Warwick in exchange for which (i) Warwick transferred to RedHawk Pharma 247,269 preference shares in EcoGen; (ii) Scarlett surrendered 10,000,000 shares of RedHawk common stock (“RedHawk Shares”); and, (iii) the shareholders of Scarlett and Warwick paid RedHawk certain cash consideration.

With the completion of the Share Transfer Agreement, RedHawk Pharma now owns approximately $545,000 of preference shares and 75% of the common shares in EcoGen. The Company said it is evaluating the possibility of converting its EcoGen preference shares into additional common shares to further increase its common stock ownership in EcoGen.

The RedHawk Shares were issued to Scarlett in connection with the Company’s initial March 2016 investment in EcoGen are being returned into the Company’s treasury.

RedHawk Announces First Quarter Results

LAFAYETTE, La., Nov. 22, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (IDNG) (“RedHawk” or the “Company”) announced today its results for the three-month period ended September 30, 2017 as it continues to methodically build and develop its branded generic pharmaceutical and medical device business.

For the three-month period ended September 30, 2017, the Company reported a smaller than expected consolidated net loss attributable to RedHawk of $55,464 on gross revenues of $67,893 as compared to a consolidated net loss attributable to RedHawk of $193,561 on gross revenues of $499,280 for the comparable three-month period ended September 30, 2016. The most significant change between the comparable three-month periods was the Company’s cash burn. During the three-month period ended September 30, 2017, RedHawk used cash of only $93,175 in its operating activities of which $94,455 was used to reduce trade debt as the Company continues to focus on reducing its short-term trade obligations. Excluding this reduction in trade debt, the Company’s operations would have been cash flow positive for the September 30, 2017 three-month period. Also, the cash burn from operations for the first quarter of fiscal 2018 was $150,844 better than the $244,019 of cash used by RedHawk in its operating activities during the comparable three-month period ended September 30, 2016 on far greater revenues.

RedHawk achieved this improved operating performance primarily by slashing European operating costs. Also, the Company initiated its previously announced revised marketing strategy to focus more on the sale of RedHawk’s own, more profitable, branded generic pharmaceuticals and less marketing emphasis on the sale of highly competitive and less profitable pharmaceutical products owned by third-parties. Under this new marketing strategy, the temporary reduction in top-line revenue is offset by significantly lower customer discounts, dramatically improved customer credit worthiness, consolidation of administrative personnel, lower overhead costs and an improved third-party distribution infrastructure. As future sales to Clinical Commissioning Groups and hospitals increase, RedHawk believes when fully implemented, this marketing strategy and distribution and administration improvements will continue to result in increased profitability and improved cash flows from its operating activities.

The Company also said it believes the implementation of this new marketing and distribution strategy now positions its branded generic pharmaceutical operations to successfully complete and integrate its previously announced European hospital license acquisition and strategic marketing and operational joint venture agreements.

In August 2017, the Company announced the execution of a non-binding letter of intent (“EU License Acquisition”) for the purchase of a portfolio of European (“EU”) hospital licenses to be combined with the portfolio of dossiers and licenses of EcoGen Europe Ltd. (“EcoGen”). The licenses to be acquired cover injectable anti-infective generic pharmaceuticals. RedHawk said it believes the acquisition of these licenses could result in the ultimate issuance of market authorizations in up to twelve (12) EU markets for seven (7) core anti-infective products including piperacillin-tazobactam (PipTaz), meropenum, imipenem/cilastatin and the four (4) most widely used cephalosporins

In September 2017, RedHawk Pharma UK Ltd. (“RedHawk Pharma”), a wholly-owned subsidiary of RedHawk, announced it had agreed in principle to enter into definitive marketing and operational joint venture agreements (“Joint Venture Agreements”) with ICE Pharma Group (“IPG”), a United Kingdom-based generic pharmaceutical sales and compliance company. IPG is led by David K. Bilton, a pharmaceutical healthcare veteran with 35 years of experience in global strategic procurement, supply chain management and business development.

When the EU License Acquisition is complete, RedHawk Pharma will then own approximately 120 generic EU licensing assets. The Company expects to complete the EU License Acquisition and the Joint Venture Agreements by December 31, 2017.

EcoGen Share Transfer

On March 23, 2016, RedHawk Pharma UK Ltd initially acquired a 25% equity interest in EcoGen from Scarlett Pharma Ltd (“Scarlett”). On September 12, 2017 we completed a share transfer agreement wherein we increased our ownership in EcoGen to 75%. Under the terms of the agreement reached with Scarlett and its affiliate, they will surrender ten (10) million shares of RedHawk common stock, transfer to RedHawk approximately $300,000 of EcoGen preferred stock and other consideration in exchange for RedHawk assuming approximately $370,000 of obligations due to EcoGen. The RedHawk Shares were originally issued to Scarlett in connection with the Company’s March 2016 investment into EcoGen. Upon completion of the Agreement, Pharma will own approximately $635,000 of EcoGen’s preferred stock and 75% of EcoGen’s common stock. We are in the process of completing the necessary documents and expect this agreement will be finalized in the quarter ending December 31, 2017.

 

Organizational Changes

Mr. Steven C. Bader has been appointed to RedHawk’s Board of Directors effective immediately. Mr. Bader has over 13 years of experience with interstate trucking and is the President and owner of I-44 Express, a Missouri-based provider of long-haul interstate trucking. He also has more than 25 years of entrepreneurial experience in the janitorial supply and service industries and is the owner of Spencer Office Cleaning and Sundance Janitorial Supply Co. Mr. Bader is 54 years of age and attended the University of Missouri, St Louis.      

Mr. Phillip Spizale has joined RedHawk as a healthcare advisor to the Company’s Board of Directors. Mr. Spizale has more than 20 years of sales and management experience in the healthcare industry and is currently the Chief Sales Officer for REVA, Inc., the largest fixed wing air medical transport service provider in the Americas. Prior to joining REVA, Mr. Spizale held various senior sales and managerial positions with Concentra Inc., a national health care provider of a wide range of medical services to employers and patients, including urgent care, occupational medicine, physical therapy, primary care, and wellness programs.

Mr. Spizale earned his Masters of Business Administration from Webster University in St. Louis and holds a Bachelors of Arts degree in Communication from Loyola University in New Orleans.

There are no transactions reportable pursuant to Item 404(a) of Regulation S-K in connection with either Mr. Bader’s or Mr. Spizale’s appointment.


RedHawk Reports Year End Results

LAFAYETTE, La., Nov. 01, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (IDNG) (“RedHawk” or the “Company”) announced today a consolidated net loss of $407,681 on revenues of $1,670,488 (net revenues of $929,859) for the twelve month period ended June 30, 2017. The 2017 fiscal year end results include approximately $300,000 of non-recurring litigation and transactional costs. The June 30, 2017 fiscal year end results compare to a consolidated net loss of $1,267,960 on minimal revenues for the comparable twelve month period ended June 30, 2016. The net loss for the fiscal year ended June 30, 2016 included a non-recurring gain of $156,697 resulting from the expiration of certain indebtedness. Excluding this non-recurring gain, the Company reported a net loss of $1,424,657 for the twelve month period ended June 30, 2016.

The improved year-over-year performance resulted primarily from greater revenues from EcoGen Europe, Ltd. (“EcoGen”), RedHawk’s United Kingdom based provider of branded generic pharmaceuticals and “specials”. The Company said EcoGen is exiting the highly competitive market for “specials” and will instead focus exclusively on providing EcoGen’s branded generics to Clinical Commissioning Groups. While EcoGen will initially experience lower revenues with this new marketing emphasis, the Company said it believes this restructured marketing strategy will ultimately result in smaller customer discounts, improved profitability, significantly lower personnel and overhead costs, greater operating efficiencies and superior customer credit worthiness. Further, the Company said it believes the more streamlined operations resulting from this new marketing restructure will better position EcoGen’s branded generic operations for the completion, the acceptance and the ultimate efficient integration of RedHawk’s recently announced strategic acquisition of additional branded generic dossiers and licenses. 

In August 2017, the Company announced the execution of a non-binding letter of intent (“EU License Acquisition”) for the purchase of a portfolio of European (“EU”) hospital licenses to be combined with EcoGen’s portfolio of dossiers and licenses. The licenses to be acquired cover injectable anti-infective generic pharmaceuticals. RedHawk said it believes the acquisition of these licenses could result in the ultimate issuance of market authorizations in up to twelve (12) EU markets for seven (7) core anti-infective products including piperacillin-tazobactam (PipTaz), meropenum, imipenem/cilastatin and the four (4) most widely used cephalosporins

In September 2017, RedHawk Pharma UK Ltd. (“RedHawk Pharma”), a wholly-owned subsidiary of RedHawk, announced it had agreed in principle to enter into definitive marketing and operational joint venture agreements (“Joint Venture Agreements”) with ICE Pharma Group (“IPG”), a United Kingdom-based generic pharmaceutical sales and compliance company. IPG is led by David K. Bilton, a pharmaceutical healthcare veteran with 35 years of experience in global strategic procurement, supply chain management and business development.

Also in September 2017, the Company announced that RedHawk Pharma had completed the previously announced share transfer agreement to increase its ownership position in EcoGen to 75%. The Company additionally announced that RedHawk Pharma had reached an agreement in principle (“Agreement”) with Scarlett Pharma Ltd. (“Scarlett”) and an affiliate, whereby Pharma would further increase its equity position in EcoGen. Under the terms of the Agreement, Scarlett and its affiliate will surrender to the Company 10 million shares of RedHawk’s outstanding common stock (the “RedHawk Shares”), transfer to RedHawk Pharma approximately $300,000 of EcoGen’s preferred stock plus other consideration in exchange for RedHawk Pharma assuming approximately $370,000 of obligations due to EcoGen. The RedHawk Shares were originally issued to Scarlett in connection with the Company’s March 2016 investment into EcoGen.

Upon completion of the Agreement, RedHawk Pharma will own approximately $635,000 of EcoGen’s preferred stock and 75% of EcoGen’s common stock with further ownership increases possible. When the EU License Acquisition is complete, RedHawk Pharma will own approximately 120 generic EU licensing assets. The Company expects the Agreement, the EU License Acquisition and the Joint Venture Agreements will be completed by the end of the fourth calendar quarter of 2017.


****RedHawk Engages MD Global Partners****10/13/2017 
https://finance.yahoo.com/news/redhawk-engages-md-global-partners-160000649.html 

****RedHawk Increases Stake in EcoGen****9/27/2017 
https://finance.yahoo.com/news/redhawk-increases-stake-ecogen-150000133.html 

****RedHawk Pharma Agrees to Complete Marketing and Operational Joint Venture Agreement****9/18/2017 
http://www.otcmarkets.com/stock/IDNG/news/RedHawk-Pharma-Agrees-to-Complete-Marketing-and-Operational-Joint-Venture-Agreement?id=170046&b=y 


****RedHawk Increases Ownership in EcoGen****9/6/2017 
http://www.otcmarkets.com/stock/IDNG/news/RedHawk-Increases-Ownership-in-EcoGen?id=169026&b=y 


****RedHawk Land Announces Lease Renewals****8/3/2017 
http://www.otcmarkets.com/stock/IDNG/news/RedHawk-Land-Announces-Lease-Renewals?id=166327&b=y 


****RedHawk Increases Ownership in EcoGen****8/2/2017 
http://www.otcmarkets.com/stock/IDNG/news/RedHawk-Increases-Ownership-in-EcoGen?id=166162&b=y 


****RedHawk Reports Third Quarter Earnings****6/14/2017 
https://finance.yahoo.com/news/redhawk-reports-third-quarter-earnings-193000491.html 


****RedHawk Announces Troubled EcoGen Due Diligence Results****5/2/2017 
https://finance.yahoo.com/news/redhawk-announces-troubled-ecogen-due-160000802.html 


****RedHawk Announces Second Quarter Results****3/13/2017 
https://finance.yahoo.com/news/redhawk-announces-second-quarter-results-200000192.html 


**** RedHawk Commences Sale of Branded Generics to Clinical Commissioning Groups****2/28/2017 
https://finance.yahoo.com/news/redhawk-commences-sale-branded-generics-170000001.html 


****RedHawk to Expand Innovation Center Offices****2/21/2017 
https://finance.yahoo.com/news/redhawk-expand-innovation-center-offices-133000076.html 


****RedHawk Sues Former Executive****1/31/2017 
https://finance.yahoo.com/news/redhawk-sues-former-executive-210000558.html 


****RedHawk Holdings Woundclot Approved for NHS Supply Chain****12/22/2016 
https://upticknewswire.com/woundclot-approved-for-nhs-supply-chain/?utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+UptickNewswire+%28Uptick+Newswire%29 


****Redhawk Announces First Quarter Results**** 
https://finance.yahoo.com/news/redhawk-announces-first-quarter-results-210000446.html 


****RedHawk Announces Year End Results****10/31/2016 
https://finance.yahoo.com/news/redhawk-announces-end-results-130000344.html 


****RedHawk Receives Pre-Market Clearance For Needle Destruction Unit****10/25/2016 
https://finance.yahoo.com/news/redhawk-receives-pre-market-clearance-140000178.html 


****Redhawk Acquires Stake in Tigress Energy Partners****9/26/2016 
https://finance.yahoo.com/news/redhawk-acquires-stake-tigress-energy-201000870.html 


****EcoGen Acquires Exclusive U.K. Licensing And Supply Rights For New Sildenafil Spray****8/19/2016 
http://finance.yahoo.com/news/ecogen-acquires-exclusive-u-k-143000573.html 


****Ecogen Completes Regulatory Certifications And Enters Into Exclusive United Kingdom Distribution Agreement****8/15/16 
http://finance.yahoo.com/news/ecogen-completes-regulatory-certifications-enters-150000311.html 


****Redhawk Agrees to Acquire Majority Stake in Mint Leasing, Inc.****7/27/2016 
http://finance.yahoo.com/news/redhawk-agrees-acquire-majority-stake-133000768.html 


****RedHawk Provides Updates****7/11/2016 
http://finance.yahoo.com/news/redhawk-provides-updates-140000144.html 


****Kav Singh Hundle Appointed To RedHawk Board Of Directors****6/2/2016 
http://finance.yahoo.com/news/kav-singh-hundle-appointed-redhawk-133000161.html 


****RedHawk Reports Third Quarter Results****5/23/2016 
http://finance.yahoo.com/news/redhawk-reports-third-quarter-results-191600054.html 


****RedHawk in Advanced Discussions to Acquire Pharma Manufacturer****5/16/2016 
http://finance.yahoo.com/news/redhawk-advanced-discussions-acquire-pharma-133500529.html 


****RedHawk Announces Board Changes****4/27/2016 
http://finance.yahoo.com/news/redhawk-announces-board-changes-171500627.html 


****RedHawk Establishes Innovation Center****4/14/2016 
http://finance.yahoo.com/news/redhawk-establishes-innovation-center-130900701.html 


****RedHawk Acquires Exclusive U.S. Manufacturing and Distribution Rights for Centri Full Body Scanner****4/11/2016 
https://finance.yahoo.com/news/redhawk-acquires-exclusive-u-manufacturing-133000669.html 

 

 




 



Visit: http://www.otcmarkets.com/stock/IDNG/company-info to see complete details.

Independence Energy Corp. is Active on the Nevada Secretary of State site:
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=CBwSAwKRC3a4pW%252bE3xV7Sw%253d%253d&nt7=0




Incorporated In: Nevada in 2012

Transfer Agent:

Transfer Online, Inc.
512 SE Salmon Street
Portland, OR 97214
Phone: 503-227-2950

http://www.transferonline.com
info@transferonline.com








http://finance.yahoo.com/q/h?s=idng



Contact Us:

REDHAWK HOLDINGS CORP.
120 Rue Beauregard
Suite 206
Lafayette, LA 70508

Website: www.redhawkholdingscorp.com
Email: info@redhawkholdingscorp.com
Phone: 337-269-5933

 
 

About RedHawk Holdings Corp.

RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the Disintegrator™ Insulin Needle Destruction Unit, the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.

SNDD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SNDD News: Current Report Filing (8-k) 09/13/2019 02:45:28 PM
SNDD News: REDHAWK ANNOUNCES APPOINTMENT OF SENIOR MEDICAL DEVICE SALES EXECUTIVE TO BOARD 09/13/2019 01:00:00 PM
SNDD News: REDHAWK ANNOUNCES NEW TRADING NAME AND TRADING SYMBOL 09/11/2019 01:00:00 PM
SNDD News: REDHAWK NAMES SUPPLY CHAIN VETERAN TO THE BOARD OF DIRECTORS 09/09/2019 11:00:00 AM
SNDD News: Securities Registration: Employee Benefit Plan (s-8) 08/21/2019 05:13:20 PM
PostSubject
#35468  Sticky Note Third news today: APPOINTMENT OF SENIOR MEDICAL DEVICE times2times2 09/13/19 03:22:08 PM
#34601  Sticky Note REDHAWK ANNOUNCES NEW TRADING NAME AND TRADING SYMBOL Golden_Cross 09/11/19 05:32:28 PM
#33247  Sticky Note Updates: Sales of SANDD mini™ device; Famous DR. times2times2 08/22/19 09:53:19 AM
#33206  Sticky Note News: Employee Benefit plan - Dr Drew Pinsky, times2times2 08/21/19 05:33:41 PM
#32724  Sticky Note REDHAWK NAMES DR. DREW PINSKY AS NATIONAL SPOKESPERSON MNKD_RISE 08/15/19 01:34:36 PM
#35581   Especially if regulations change. reaper8555 09/15/19 01:58:35 AM
#35580   Sept ,15th today reaper8555 09/15/19 01:48:31 AM
#35579   This is the kind of product that insurance tbdelephant 09/15/19 12:04:47 AM
#35578   Sandd product is amazing. Before my mother's passing reaper8555 09/15/19 12:01:05 AM
#35577   Sorry their whole lives. reaper8555 09/14/19 11:54:09 PM
#35576   Some search they're whole life for this type reaper8555 09/14/19 11:53:27 PM
#35575   Yep and we have ourselves a gem. reaper8555 09/14/19 11:52:33 PM
#35574   Perfect way of putting it... I agree with Thee Z 09/14/19 11:02:54 PM
#35573   Klug has the dream team. reaper8555 09/14/19 10:56:00 PM
#35572   WOW! Incredible! Only regret I have is I Thee Z 09/14/19 10:47:22 PM
#35571   I agree Cashking74 09/14/19 07:06:06 PM
#35570   Thank you. Loaded last week. The texasholdem 09/14/19 06:18:07 PM
#35568   Awesome, cool post. AlwaysRed 09/14/19 05:40:28 PM
#35567   Wow... A living example of Klug’s success! Thanks for sharing MNKD_RISE 09/14/19 05:24:12 PM
#35566   Amazing Post. Thank you for Sharing. Regards Smitter smitter 09/14/19 05:22:14 PM
#35565   I WAS an omni shareholder when Eckerd and milesp52 09/14/19 05:15:30 PM
#35564   Update to share count No change to Share structure MNKD_RISE 09/14/19 05:01:31 PM
#35563   Here's a link to an interview with Darcy Divest 09/14/19 04:25:39 PM
#35562   MUST READ: Leadership is important About our CFO, Mr MNKD_RISE 09/14/19 02:51:39 PM
#35561   Let me add this On top of that Think MNKD_RISE 09/14/19 02:22:20 PM
#35560   boom!! Zog1 09/14/19 02:09:28 PM
#35559   Talk to me about military bases, just about Zog1 09/14/19 02:07:33 PM
#35558   If there is 10,000 schools in Texas and Zog1 09/14/19 01:39:22 PM
#35557   Come on 7, don't tease me like that ghostrider19 09/14/19 01:30:27 PM
#35556   Very nice synopsis, well thought out and covers Diamond_Dog 09/14/19 01:27:42 PM
#35555   Let’s go baby Zog1 09/14/19 01:15:30 PM
#35554   Absolutely!! No worries here!! 714 09/14/19 12:51:35 PM
#35553   These guys are professionals and they plan well. AlwaysRed 09/14/19 12:40:40 PM
#35552   Actually there was quite a bit available, I Diamond_Dog 09/14/19 12:32:02 PM
#35551   Am thinking the same, esp if we hear MNKD_RISE 09/14/19 12:24:16 PM
#35550   I’m thinking .01++ next week!! 714 09/14/19 12:17:50 PM
#35549   Exactly. Right now it can't even hold the ghostrider19 09/14/19 12:06:57 PM
#35548   Investment here. Come Back in a few years and ThoughtPower 09/14/19 11:29:16 AM
#35547   FDA Approved & OSHA Compliant HUGE BOOM!!! 714 09/14/19 09:25:34 AM
#35546   https://www.needledestructiondevice.com ElvisFunk 09/14/19 09:01:25 AM
#35545   That almost happened to me. I had bought Divest 09/14/19 08:14:37 AM
#35544   Good morning SNDD StaleyCornell 09/14/19 08:03:53 AM
#35543   Divest, not_on_the_rug....good to see you VSTR guys here. lumpy9200 09/14/19 02:58:09 AM
#35542   Next week!! Possibly Monday we go above .008!! 714 09/13/19 11:13:32 PM
#35541   I believe that you will see the price AlwaysRed 09/13/19 10:53:01 PM
#35540   Lets close and hold a base at 0.008 ghostrider19 09/13/19 10:47:13 PM
#35539   Any government contracts would set this into orbit. Not_on_the_rug 09/13/19 10:11:12 PM
#35538   Only new to this stock..been dealing with pennies Thee Z 09/13/19 09:22:48 PM
#35537   That's what I'm banking on... Everything is lining Thee Z 09/13/19 09:20:37 PM
#35536   You know they are lobbing for law changes Codyco 09/13/19 09:12:55 PM
#35535   Wait till its Medicare and Medicaid approved Codyco 09/13/19 09:11:55 PM
#35534   Glad to see you're on here. I only Not_on_the_rug 09/13/19 09:08:02 PM
#35533   FDA approved... Gooddolphin 09/13/19 08:47:03 PM
#35532   Huge!!!!! Silver very possible!!! 714 09/13/19 08:44:33 PM
#35531   Scroll to the bottom....RedHawk!! laundryguy 09/13/19 08:24:34 PM
PostSubject